KATE NEMECEK: Open Payments
NPI 1326596602 · BREA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,973 in 82 payments from 20 companies in 2025. Trend: 2023 $899 · 2024 $1,211 · 2025 $1,973
Food & beverage: $1,899Education: $74
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $273 |
| Regeneron Healthcare Solutions, Inc. | 11 | $257 |
| Amgen Inc. | 9 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $190 |
| GENZYME CORPORATION | 14 | $182 |
| KYOWA KIRIN, INC. | 3 | $160 |
| GlaxoSmithKline, LLC. | 12 | $151 |
| Novartis Pharmaceuticals Corporation | 4 | $113 |
| BioCryst US Sales Co., LLC | 3 | $87 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $68 |
Products named: DUPIXENT, TEZSPIRE, CUVITRU, NUCALA, ORLADEYO, RUCONEST, ORALAIR, Sajazir.
Industry payments across CA — which companies pay providers there.
